JP2009519025A5 - - Google Patents

Download PDF

Info

Publication number
JP2009519025A5
JP2009519025A5 JP2008545009A JP2008545009A JP2009519025A5 JP 2009519025 A5 JP2009519025 A5 JP 2009519025A5 JP 2008545009 A JP2008545009 A JP 2008545009A JP 2008545009 A JP2008545009 A JP 2008545009A JP 2009519025 A5 JP2009519025 A5 JP 2009519025A5
Authority
JP
Japan
Prior art keywords
seq
heavy chain
chain variable
variable region
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008545009A
Other languages
English (en)
Japanese (ja)
Other versions
JP5015949B2 (ja
JP2009519025A (ja
Filing date
Publication date
Priority claimed from GBGB0525662.3A external-priority patent/GB0525662D0/en
Application filed filed Critical
Publication of JP2009519025A publication Critical patent/JP2009519025A/ja
Publication of JP2009519025A5 publication Critical patent/JP2009519025A5/ja
Application granted granted Critical
Publication of JP5015949B2 publication Critical patent/JP5015949B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008545009A 2005-12-16 2006-12-14 Nogoを標的とする免疫グロブリン Expired - Fee Related JP5015949B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0525662.3 2005-12-16
GBGB0525662.3A GB0525662D0 (en) 2005-12-16 2005-12-16 Immunoglobulins
PCT/EP2006/069737 WO2007068750A2 (en) 2005-12-16 2006-12-14 Immunoglobulins directed against nogo

Publications (3)

Publication Number Publication Date
JP2009519025A JP2009519025A (ja) 2009-05-14
JP2009519025A5 true JP2009519025A5 (enExample) 2011-11-10
JP5015949B2 JP5015949B2 (ja) 2012-09-05

Family

ID=35736284

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008545009A Expired - Fee Related JP5015949B2 (ja) 2005-12-16 2006-12-14 Nogoを標的とする免疫グロブリン

Country Status (30)

Country Link
US (2) US8362208B2 (enExample)
EP (2) EP2228391A3 (enExample)
JP (1) JP5015949B2 (enExample)
KR (1) KR101355118B1 (enExample)
CN (1) CN101374863B (enExample)
AR (1) AR057239A1 (enExample)
AU (1) AU2006325228B2 (enExample)
BR (1) BRPI0619855A2 (enExample)
CA (1) CA2633501C (enExample)
CR (1) CR10099A (enExample)
CY (1) CY1113094T1 (enExample)
DK (1) DK1960429T3 (enExample)
EA (1) EA015536B1 (enExample)
ES (1) ES2389380T3 (enExample)
GB (1) GB0525662D0 (enExample)
HR (1) HRP20120684T1 (enExample)
IL (1) IL192086A0 (enExample)
JO (1) JO2795B1 (enExample)
MA (1) MA30041B1 (enExample)
MY (1) MY149492A (enExample)
NO (1) NO20082699L (enExample)
NZ (1) NZ569143A (enExample)
PE (1) PE20071099A1 (enExample)
PL (1) PL1960429T3 (enExample)
PT (1) PT1960429E (enExample)
SI (1) SI1960429T1 (enExample)
TW (1) TWI378940B (enExample)
UA (1) UA96279C2 (enExample)
WO (1) WO2007068750A2 (enExample)
ZA (2) ZA200805111B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009151717A2 (en) 2008-04-02 2009-12-17 Macrogenics, Inc. Bcr-complex-specific antibodies and methods of using same
PL2207808T3 (pl) * 2007-11-02 2013-11-29 Novartis Ag Ulepszone cząsteczki wiążące się z Nogo-A i ich zastosowania farmaceutyczne
TW201012489A (en) 2008-05-06 2010-04-01 Glaxo Group Ltd Encapsulation of biologically active agents
CA2730473A1 (en) * 2008-07-11 2010-01-14 Glaxo Group Limited Novel treatment
US8828390B2 (en) 2010-07-09 2014-09-09 Universitat Zurich Uses of NOGO-A inhibitors and related methods
BR112014032987A2 (pt) 2012-07-05 2017-06-27 Glaxo Group Ltd método de tratamento ou profilaxia de um distúrbio neurológico
US20180362660A1 (en) * 2016-05-09 2018-12-20 Schickwann Tsai Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes
US11013815B2 (en) 2017-06-14 2021-05-25 Monojul, Llc High-affinity anti-human folate receptor beta antibodies and methods of use
MX2021015473A (es) * 2019-06-13 2022-04-20 Prestige Biopharma Pte Ltd Nuevo anticuerpo específico para cthrc1 y su uso.
US20230399390A1 (en) 2019-10-24 2023-12-14 Novago Therapeutics Ag Novel anti-nogo-a antibodies
GB202012331D0 (en) 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
WO2022263864A1 (en) 2021-06-17 2022-12-22 Petmedix Ltd Anti canine cd20 antibodies
WO2023067358A1 (en) 2021-10-21 2023-04-27 Petmedix Ltd Proteins comprising the extracellular domain of p75ntr
CN116251181B (zh) * 2021-12-02 2023-09-22 北京东方百泰生物科技股份有限公司 一种抗tslp单克隆抗体的注射制剂
WO2023152486A1 (en) 2022-02-09 2023-08-17 Petmedix Ltd Therapeutic antibodies
WO2024041450A1 (zh) * 2022-08-22 2024-02-29 舒泰神(北京)生物制药股份有限公司 特异性识别Nogo-A的抗体及其应用
GB202217993D0 (en) 2022-11-30 2023-01-11 Petmedix Ltd Therapeutic antibodies
WO2024165872A1 (en) 2023-02-09 2024-08-15 Petmedix Ltd Therapeutic molecules comprising variants of the extracellular domain of p75 neurotrophin receptor (p75ntr)

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
GB9403250D0 (en) 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
DE69533408T2 (de) 1994-05-27 2005-09-08 Glaxosmithkline S.P.A. Chinolinderivate als Tachykinin NK3 Rezeptor Antagonisten
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
DE69633336T2 (de) 1995-06-27 2005-09-22 Research Foundation Of Cuny Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält
US6420338B1 (en) * 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
PT1098972E (pt) 1998-07-22 2010-12-14 Smithkline Beecham Ltd Proteína semelhante a proteína especificamente neuroendócrina e adnc codificante
CN101684155A (zh) 1998-11-06 2010-03-31 苏黎世大学 Nogo基因的核苷酸序列和蛋白序列以及基于其的方法
FR2792199B3 (fr) 1999-04-13 2001-05-18 Sanofi Sa Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur
JP2005538706A (ja) 2001-07-12 2005-12-22 ジェファーソン フーテ, スーパーヒト化抗体
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0318727D0 (en) 2003-08-08 2003-09-10 Smithkline Beecham Corp Novel compounds
DE10338136A1 (de) 2003-08-15 2005-03-24 European Molecular Biology Laboratory Zentrifuge und ein Träger zur Verwendung in einer Zentrifuge
GB0321997D0 (en) 2003-09-19 2003-10-22 Novartis Ag Organic compound
CA2549956C (en) * 2003-12-22 2016-04-12 Glaxo Group Limited Immunoglobulins
AU2005207003C1 (en) * 2004-01-20 2013-06-13 Humanigen, Inc. Antibody specificity transfer using minimal essential binding determinants
US7973139B2 (en) * 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor

Similar Documents

Publication Publication Date Title
JP2009519025A5 (enExample)
RU2421464C2 (ru) Человеческие антитела к il-13 и их терапевтическое применение
RU2362780C2 (ru) Nogo-a-нейтрализующие иммуноглобулины для лечения неврологических заболеваний
JP2014502955A5 (enExample)
RU2015143242A (ru) Антитела против gdf8 человека
JP2006506942A5 (enExample)
JP2019511222A5 (enExample)
JP2017500018A5 (enExample)
JP2019527543A5 (enExample)
JP2018506277A5 (enExample)
JP2018535948A5 (enExample)
HRP20150799T1 (hr) Sastavi i postupci za protutijela protiv komplementnog proteina c5
IL272674B2 (en) Preparations for use in the treatment or prevention of graft-versus-graft disease or disseminated intravascular hemorrhage or veno-occlusive disease associated with hematopoietic stem cell transplantation
RU2011137369A (ru) Способы лечения воспаления в нейронной ткани с применением моноклонального антитела или его связывающего фрагмента
JP2019527194A5 (enExample)
EP3008093A1 (en) Anti-her2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer
WO2009086539A4 (en) Treatment and prophylaxis of amyloidosis
RU2011152816A (ru) ПРИМЕНЕНИЕ АНТИТЕЛА ПРОТИВ Tau pS422 ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ГОЛОВНОГО МОЗГА
JP2011506483A5 (enExample)
CA2618681A1 (en) Identification and engineering of antibodies with variant fc regions and methods of using same
JP2018510617A5 (enExample)
JP2016519650A5 (enExample)
TW201219568A (en) Antibody targeting osteoclast-related protein Siglec-15
JP2019530427A5 (enExample)
JP2016502515A5 (enExample)